10 analysts have expressed a variety of opinions on Medtronic (NYSE:MDT) over the past quarter, offering a diverse set of opinions from bullish to bearish.

The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months.

	Bullish	Somewhat Bullish	Indifferent	Somewhat Bearish	Bearish
Total Ratings	3	4	3	0	0
Last 30D	1	0	0	0	0
1M Ago	2	2	2	0	0
2M Ago	0	1	0	0	0
3M Ago	0	1	1	0	0

The 12-month price targets, analyzed by analysts, offer insights with an average target of $113.0, a high estimate of $121.00, and a low estimate of $100.00. This current average reflects an increase of 0.78% from the previous average price target of $112.12.

Understanding Analyst Ratings: A Comprehensive Breakdown

The analysis of recent analyst actions sheds light on the perception of Medtronic by financial experts. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.

Analyst	Analyst Firm	Action Taken	Rating	Current Price Target	Prior Price Target
Mike Matson	Needham	Maintains	Buy	$120.00	$120.00
Robbie Marcus	JP Morgan	Lowers	Neutral	$100.00	$105.00
Matt Miksic	Barclays	Raises	Overweight	$118.00	$116.00
David Rescott	Baird	Lowers	Neutral	$100.00	$103.00
Mike Matson	Needham	Lowers	Buy	$120.00	$121.00
Matt Miksic	Barclays	Announces	Overweight	$116.00	-
Mike Matson	Needham	Announces	Buy	$121.00	-
Lee Hambright	Bernstein	Raises	Outperform	$112.00	$111.00
Matt Miksic	Barclays	Raises	Overweight	$116.00	$111.00
Richard Newitter	Truist Securities	Lowers	Hold	$107.00	$110.00

Key Insights:

• Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Medtronic. This information offers a snapshot of how analysts perceive the current state of the company.
• Rating: Analysts unravel qualitative evaluations for stocks, ranging from 'Outperform' to 'Underperform'. These ratings offer insights into expectations for the relative performance of Medtronic compared to the broader market.
• Price Targets: Understanding forecasts, analysts offer estimates for Medtronic's future value. Examining the current and prior targets provides insight into analysts' changing expectations.

Considering these analyst evaluations in conjunction with other financial indicators can offer a comprehensive understanding of Medtronic's market position. Stay informed and make well-informed decisions with our Ratings Table.

Stay up to date on Medtronic analyst ratings.

Discovering Medtronic: A Closer Look

One of the largest medical-device companies, Medtronic develops and manufactures therapeutic medical devices for chronic diseases. Its portfolio includes pacemakers, defibrillators, transcatheter heart valves, stents, insulin pumps, spinal fixation devices, neurovascular products, advanced energy, ablation laser therapy, and surgical tools. The company primarily markets its products to healthcare institutions and physicians in the United States, Western Europe, and Japan. Foreign sales account for roughly 50% of the company's total sales.

Understanding the Numbers: Medtronic's Finances

Market Capitalization: Surpassing industry standards, the company's market capitalization asserts its dominance in terms of size, suggesting a robust market position.

Revenue Growth: Medtronic's revenue growth over a period of 3M has been noteworthy. As of 31 January, 2026, the company achieved a revenue growth rate of approximately 8.74%. This indicates a substantial increase in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Health Care sector.

Net Margin: Medtronic's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of 12.68%, the company showcases strong profitability and effective cost management.

Return on Equity (ROE): Medtronic's ROE is below industry standards, pointing towards difficulties in efficiently utilizing equity capital. With an ROE of 2.34%, the company may encounter challenges in delivering satisfactory returns for shareholders.

Return on Assets (ROA): Medtronic's ROA is below industry averages, indicating potential challenges in efficiently utilizing assets. With an ROA of 1.25%, the company may face hurdles in achieving optimal financial returns.

Debt Management: Medtronic's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 0.57.

The Significance of Analyst Ratings Explained

Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.

Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.

This article was generated by Benzinga's automated content engine and reviewed by an editor.